Biomarkers for Psychiatric Drugs: Outlier or Opportunity?
A handful of companies are pursuing predictive genetic tests for evaluating psychiatric drugs. The need is apparent, and an early success could trigger a rapid shift in thinking about the sustainability of building a business around biomarkers in a therapeutic area sometimes considered the least likely to benefit near term from their development. That said, firms in this area--and elsewhere--must be wary of leaning too heavily on pharma companies as supportive partners.
You may also be interested in...
Will COX-2 + Biomarker = Success? Novartis Tests the Frontiers of Companion Diagnostics
A new genetic blood test that identifies patients at risk of liver toxicities may give Joicela (formerly Prexige) new life.
Clinical Data Psyched For Vilazodone NDA Filing In Second Half
Clinical Data has kicked off what could prove to be a pivotal year with a flurry of activity, including a new financing, the sale of its Cogenix pharmacogenomics services arm, and the publication of important clinical trial results. But investors are more concerned with what's coming in a couple of months: results from a second pivotal trial for its lead therapeutic candidate vilazodone and the subsequent NDA filing
What New Her2 Tests Say about Personalized Medicine
Traditional diagnostic tests for Her2 (the target of the drug Herceptin) have well-documented failings. In July, Monogram Biosciences launched a new Her2 test, and two months later, Genomic Health added Her2 status information to its breast cancer test. They believe that more comprehensive, multianalyte tests may better guide therapy and yield a pharmacoeconomic benefit, even at eight to 10 times the cost. These developments point to the need for a more nuanced approach to the management of cancer as a chronic disease and a more nuanced view of personalized medicine.